NASDAQ:AGIO
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.'s revenue grew 48.0% in fiscal 2025 to $54.0M while operating margin rose to −873.9%, its highest in 4 years. Free cash flow was −$377.3M, −698.3% of revenue.Summary generated from Agios Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$54.0M
Revenue growth+48.0%
Revenue, 5-yr CAGRn/a
Gross margin88.3%
Operating margin−873.9%
Net margin−764.0%
ROICn/a
Return on equity−30.2%
Debt / equityn/a
Free cash flow−$377.3M
FCF margin−698.3%
Share count change+0.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 14 | 27 | 36 | 54 |
| Operating income | −378 | −389 | −391 | −426 | −472 |
| Net income | 1,605 | −232 | −352 | 674 | −413 |
| Free cash flow | −413 | −314 | −297 | −392 | −377 |
Recent filings
- 4Insider transaction report
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 4Insider transaction report
Jul 10, 2026 - 8-KDirector or officer change
Jun 18, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 29, 2026 - 8-KResults of operations and financial condition
Apr 29, 2026 - DEF 14AProxy statement
Apr 24, 2026